TD Cowen Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed ...
Scotiabank Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Scotiabank analyst Greg Harrison maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report) today and set a price target of $22.00.
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Hosted on MSN14h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer Drugs
Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
Hosted on MSN19h
BridgeBio Oncology and Helix enter definitive merger agreement
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
The Pharma Letter22h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...